Table 1.
Clinicopathological patient characteristics
| Case | Age | Gender | Lymph node | Previous treatment | Cytology† (Papanicolaou) | Histolology†,‡ (H&E) | IHC for neuroendocrine markers‡ | ||
|---|---|---|---|---|---|---|---|---|---|
| CD56 | Synaptophysin | Chromogranin A | |||||||
| 1 | 69 | M | 7 | Surgery | Carcinoma | Neuroendocrine | − | − | − |
| 2 | 75 | M | 4L | Surgery + adjuvant chemotherapy | Carcinoma | Neuroendocrine | − | − | − |
| 3 | 54 | M | 4R | None | LCNEC | Not determined | NA | NA | NA |
| 4 | 74 | M | 4R | None | No malignancy | Neuroendocrine | − | − | − |
| 5 | 76 | M | 4L | Surgery + adjuvant chemotherapy | LCNEC suspected | Neuroendocrine | + | − | + |
| 6 | 77 | M | 4R | None | Carcinoma | Neuroendocrine | + | + | + |
| 7 | 36 | M | 4R | None | LCNEC suspected | Neuroendocrine | − | + | − |
| 8 | 68 | M | 7 | Surgery | No malignancy | Neuroendocrine | + | + | + |
| 9 | 71 | M | 4R | None | Carcinoma | Neuroendocrine | + | + | − |
| 10 | 62 | M | 7 | None | LCNEC suspected | Neuroendocrine | + | − | + |
| 11 | 69 | M | 4R | None | LCNEC suspected | Neuroendocrine | + | + | + |
| 12 | 77 | M | 4R | None | LCNEC suspected | Neuroendocrine | + | + | + |
| 13 | 67 | M | 4R | None | Carcinoma | Neuroendocrine | + | + | + |
†
Diagnosis using 2004 World Health Organization (WHO) classification;
‡
revised diagnosis using 2015 WHO classification. Neuroendocrine refers to neuroendocrine morphology: neuroendocrine architecture with a granular chromatin pattern in the nuclei and a rosette‐like pattern.
H&E, hematoxylin and eosin; IHC, immunohistochemistry; LNCEC, large cell neuroendocrine carcinoma; NA, not applicable.